Latest Health News
World Health Day 2026 Launches 'Together for Health. Stand with Science' Campaign
World Health Day on April 7, 2026, launches a year-long campaign under the theme 'Together for health. Stand with science,' emphasizing scientific collaboration and the One Health approach. Key events include the International One Health Summit hosted by WHO and France, and the Global Forum of WHO Collaborating Centres gathering 800 institutions from 80 countries. The campaign urges governments, scientists, and the public to engage with evidence and support science-led solutions.
UK Global Health Summit 2026 Addresses Health Worker Shortages and Climate Impacts
Tanzania participates in the UK Global Health Summit in London from March 16-18, led by Ministry of Health Permanent Secretary Seif Shekalaghe. Discussions highlight shortages of health workers, rising healthcare demands, financial pressures, and climate change effects on public health. WHO Director-General Dr. Tedros stressed strengthening global partnerships and resilient health systems.
Measles Outbreaks Spark Concerns for North American and Global Health Security
CSIS discusses ongoing measles outbreaks and elimination efforts in North America, warning of implications for regional and global health security from sustained transmission. Recent events and podcasts, including conversations with experts like Natasha Crowcroft, analyze resurgence in the US and policy needs.
The Bipartisan Alliance for Global Health Security emphasizes urgent prevention measures.
Breakthrough T1D Research at ATTD 2026 Shows Promise in Immune-Evasive Islet Transplants
First-in-human trial of gene-edited, immune-evasive islet cells from deceased donors transplanted into a T1D patient's forearm demonstrated safety and C-peptide production, indicating beta cell function. Levels temporarily declined but recovered, suggesting potential without long-term immunosuppression.
Researchers aim to validate in larger studies for T1D cures.
Lundbeck Presents Phase 1b Data on Novel Parkinson's Compound Lu AF28996 at AD/PD 2026
H. Lundbeck A/S announced new Phase 1b proof-of-mechanism trial results for Lu AF28996, a novel compound for Parkinson's disease, at AD/PD 2026. The data advances research into potential new treatments.
Further details highlight its invention by Lundbeck for disease modification.
Akeso Launches Global First-in-Class Trispecific Antibody AK150 for Immunotherapy Resistance
Akeso announced clinical trials for AK150 (ILT2/ILT4/CSF1R), a trispecific antibody targeting immunotherapy resistance in cancer. This proprietary first-in-class therapy aims to overcome resistance mechanisms.
It represents a triple-target approach for advanced treatments.
Johnson & Johnson Reports Promising Erda-iDRS Results for Non-Muscle-Invasive Bladder Cancer
Johnson & Johnson shared first-in-human Phase 1 results for Erda-iDRS (formerly TAR-210) in intermediate-risk non-muscle-invasive bladder cancer, showing promising efficacy. The open-label, multicenter study evaluated intravesical delivery.
Findings support further development.
New CAR-T Strategy Prolongs Effectiveness Against Cancer and HIV
Albert Einstein College of Medicine team developed multi-cytokine scaffold-engineered CAR-T cells that fight cancer and HIV longer. The approach dramatically extends immune cell effectiveness post-infusion.
It opens avenues for durable therapies.
Euronews Health Summit Debates AI's Role in Reshaping Healthcare Ethically
Experts at the March 17 Brussels summit discuss AI's transformation of healthcare amid ethical concerns like data biases and inequalities. Partnerships like Gates Foundation and OpenAI fund AI in African clinics.
Key issues include regulation and equitable access.
Pesticide Exposure Pre-Conception Linked to Lower Newborn Apgar Scores
University of Arizona study finds women exposed to agricultural pesticides before pregnancy have newborns with poorer Apgar scores, risking health. Exposures correlate with adverse birth outcomes.
Urgent prevention needed for reproductive health.
Semaglutide Reduces Cardiovascular Risk by 20% in T1D Patients
Data from ATTD 2026 shows semaglutide lowers CVD event risk by 20% over five and ten years in T1D, per cardiovascular prediction tools. This GLP-1 therapy demonstrates potential for heart health in diabetes.
Larger trials warranted.
Vertex's Zimislecel Manufactured Islets Show Optimism in T1D Phase Trials
Vertex Pharmaceuticals' phase 1/2/3 trial data for zimislecel, infused islet cells with immunosuppression, reinforces safety and function in T1D. Consistent with traditional transplants, it fuels cure optimism.
Presented by Dr. Trevor Reichman.